Get the Stockscreener App
1.02
1.92%
-0.02
After Hours:
1.08
0.06
+5.88%
Silexion Therapeutics Corp stock is traded at $1.02, with a volume of 17,272.
It is down -1.92% in the last 24 hours and down -36.45% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$1.04
Open:
$1.1
24h Volume:
17,272
Relative Volume:
0.35
Market Cap:
$4.16M
Revenue:
-
Net Income/Loss:
$-11.91M
P/E Ratio:
-0.115
EPS:
-8.8661
Net Cash Flow:
$-10.83M
1W Performance:
-8.93%
1M Performance:
-36.45%
6M Performance:
-72.80%
1Y Performance:
-91.39%
1-Day Range:
$1.02
$1.10
1-Week Range:
$0.9701
$1.16
52-Week Range:
$0.9701
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.02 | 4.24M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
SLXNW SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
SLXN Stock Price, Quote & Chart | SILEXION THERAPEUTICS CORP (NASDAQ:SLXN) - ChartMill
Silexion (SLXN) plans big share boost, richer equity pool and reverse split - Stock Titan
Aug Chart Watch: Whats the profit margin of Silexion Therapeutics Corp2026 Geopolitical Influence & Safe Entry Point Alerts - baoquankhu1.vn
Institution Moves: Is Silexion Therapeutics Corp a strong growth stock2026 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
CEO Moves: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2026 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Fed Watch: Does GLBS stock have upside surprise potential2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Can Silexion Therapeutics Corp stock beat analyst upgradesMarket Growth Report & AI Driven Stock Price Forecasts - Bollywood Helpline
ETF Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins - baoquankhu1.vn
EBIT per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView — Track All Markets
Hedge Fund Bets: Will Silexion Therapeutics Corp Equity Warrant benefit from government policy2026 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Market Recap: Whats the profit margin of Silexion Therapeutics Corp2026 Historical Comparison & Technical Entry and Exit Alerts - baoquankhu1.vn
Shorts Report: Whats the beta of Silexion Therapeutics Corp Equity Warrant stock2026 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Top Silexion Executive Quietly Unloads a Chunk of Company Stock - TipRanks
Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction - Stock Titan
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer - geneonline.com
Investor Mood: Can Silexion Therapeutics Corp be recession proofWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Silexion Therapeutics Announces Immediate Board Membership Change - tipranks.com
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - minichart.com.sg
Silexion gets Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire
Silexion gains approval for SIL204 pancreatic cancer trial - TipRanks
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Regulators clear Silexion (NASDAQ: SLXN) to begin SIL204 pancreatic cancer trial - Stock Titan
Silexion receives Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Corp Receives Approval to Initiate Phase 2/3 Clinical Trial Of SIL204 in Locally Advanced Pancreatic Cancer - MarketScreener
Silexion Therapeutics Corp 8-K Filing – Share Capital Increase Proposal Not Approved (March 2026) - Minichart
Silexion Therapeutics Corp announced plans to submit its Phase 2/3 clinical trial application to German regulators by the end of this quarter. - bitget.com
Silexion Therapeutics shareholders reject share capital and equity plan increases By Investing.com - Investing.com South Africa
Silexion Therapeutics shareholders reject share capital and equity plan increases - Investing.com India
Shareholders at Silexion (SLXN) vote down capital and evergreen increase proposals - Stock Titan
Growth Report: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soon2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
EPS Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins2026 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Form 8K Silexion Therapeutics Corp For: 3 February - Investing.com
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Tangible book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
SLXNW Financials: Income Statement, Balance Sheet & Cash Flow | Silexion Therapeutics Corp - Stock Titan
Silexion Therapeutics Corp: Clinical-Stage KRAS Oncology Innovations and siRNA Pipeline for Pancreatic Cancer - Minichart
Silexion Therapeutics Reports 2025 Financial Results and Clinical Program Updates - geneonline.com
Biotech Silexion lines up 2026 pancreatic cancer trial after $18.6M cash raise - Stock Titan
Silexion Therapeutics 10-K: $11.9M net loss, cash $6.08M; operating loss $11.63M - TradingView
Silexion Therapeutics (NASDAQ: SLXN) outlines SIL204 KRAS cancer strategy in 10-K - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Growth Recap: Is Silexion Therapeutics Corp Equity Warrant a potential multi baggerTrade Volume Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):